Gene/Protein
Disease
Symptom
Drug
Enzyme
Compound
Pivot Concepts:
Gene/Protein
Disease
Symptom
Drug
Enzyme
Compound
Target Concepts:
Gene/Protein
Disease
Symptom
Drug
Enzyme
Compound
Query: UMLS:C0476089 (
endometrial cancer
)
11,379
document(s) hit in 31,850,051 MEDLINE articles (0.00 seconds)
Objective. The aim was to assess the intraperitoneal spread of endometrial cells during hysteroscopy. Study Design. Seventy-six women were submitted to a hysteroscopy with CO(2) under a low pressure. Group 1 had not previous diagnosis of
endometrial cancer
, and group 2 had previous diagnosis of
endometrial cancer
(stage I-92.3%). Two peritoneal washing samples were taken before (
PW1
) and immediately after (PW2) the procedure. The dissemination for the peritoneal cavity was defined by the presence of endometrial cells in the PW2; such cells should be absent in WP1. Results. Four patients were excluded for presenting endometrial cells in
PW1
. In the 72 patients left, there was no passage of cells for the peritoneal cavity. In group 1, 88% presented secretory endometrial phase with correlation of 80% between hysteroscopy and biopsy. Conclusion. Hysteroscopy performed under a low pressure of CO(2) does not cause spreading of endometrial cells into the peritoneal cavity.
...
PMID:Evaluation of the risk of spreading endometrial cell by hysteroscopy: a prospective longitudinal study. 1994 45
Long noncoding RNAs (lncRNAs) are RNA molecules more than 200 nucleotides in length that do not encode proteins. Recent studies have reported increasing numbers of functional lncRNAs. Maternally expressed gene 3 (MEG3) is a
maternally imprinted
gene encoding an lncRNA that plays a tumor suppressor role in various tumors. However, there has been rare report on mechanism of tumorigenesis and progression of
endometrial carcinoma
. In the present study, we found significantly lower MEG3 expression in
endometrial carcinoma
tissues than in normal endometrial tissues. MEG3 overexpression inhibited
endometrial cancer
cell proliferation, invasion, and metastasis; promoted apoptosis; and inhibited the activation of the phosphoinositide 3-kinase (PI3K)/m-TOR signaling pathway. RNA immunoprecipitation assay (RIP) showed that MEG3 can combine directly with PI3K. Tumor xenograft implantation in nude mice showed that MEG3 could significantly suppress tumor growth. These findings provide potential new therapeutic targets for treating
endometrial cancer
.
...
PMID:LncRNA MEG3 inhibit endometrial carcinoma tumorigenesis and progression through PI3K pathway. 2909 70